WHO ICTRP trial
Exploring a Novel Immunosuppressive Pathway in Sepsis and Its Therapeutic…
ChiCTR2600117946 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2600117946 |
|---|---|
| Public title | Exploring a Novel Immunosuppressive Pathway in Sepsis and Its Therapeutic Potential |
| Scientific title | LAG3/FGL1 Axis-Mediated CD8? T Cell Exhaustion in Sepsis-Induced Immunosuppression: Mechanisms and Targeted Intervention Research |
| Primary sponsor | Zhejiang Provincial People's Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Observational study |
| Countries | China |
| Conditions | Sepsis |
| Interventions | Sepsis patient group:None;Healthy control group:None |
| Registration date | Jan 30, 2026 |
| Target size | Sepsis patient group:30;Healthy control group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: